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Tiivistelmä 
 
Tausta: Sydän- ja verisuonitaudit ovat yleisin kuolinsyy ja suurin kansanterveysongelma 
nykymaailmassa. Hapettumalla muuntuneen LDL-liporoteiinin (oxLDL) katsotaan olevan 
keskeinen tekijä sydän- ja verisuonitauteihin johtavan ateroskleroosin synnyssä. LDL:n 
hapettumista koskevaa genetiikkaa tunnetaan huonosti. 
Tavoitteet: Työssä jatkettiin ja laajennettiin aiemmin julkaistua oxLDL:n genomin 
laajuista tutkimustamme (GWAS). Tein nyt GWAS-meta-analyysin kahdelle suurelle 
kohortille aiemmassa työssä käytettyä (HapMap2, 2.2  miljoonaa varianttia) laajemman 
1000 genomes -referenssigenomin avulla (n. 20 miljoonaa varianttia). Tavoitteena oli 
löytää uusia yhden nukleotidin polymorfismeja (SNP), jotka ovat yhteydessä LDL:n 
hapettumiseen. 
Menetelmät ja aineistot: GWAS-analyyseissa käytettiin nuorta, tervettä populaatiota (A: 
N = 2080, 45 % miehiä, ikä 32 ± 5 vuotta) ja SNPTEST-ohjelmistoa sekä 
potilaspopulaatiota (B: N = 2912, 69 % miehiä, ikä 63 ± 11 vuotta) ja ProbABEL-
ohjelmistoa. Aineistojen A ja B GWAS-meta-analyysi tehtiin GWAMA-ohjelmistolla. 
Lisäksi GWAS suoritettiin A-populaatiossa vakioimalla se aiemman tutkimuksen 
päälöydöksellä. 
Tulokset: SNP rs676210 (Pro2739Leu) apolipoproteiini B:ssä oli ainoa itsenäisesti 
oxLDL:ään liittyvä SNP (p = 8.7 x 10
-168
) GWAS meta-analyysissä. Tämä tukee aiemman 
tutkimuksemme tuloksia, mutta uusia genomin laajuisesti merkitseviä (p < 5 x10
-8
) 
tuloksia ei löytynyt. 
Johtopäätökset: Tutkimuksessa ei löydetty uusia oxLDL-tasoihin liittyviä SNP:ja. 
Seuraava vaihe on tutkia rs676210:n vaikutuksia ja sen interaktioita ympäristötekijöiden 
kanssa tarkemmin suhteessa sydän- ja verisuonitauteihin. 
  
Master’s Thesis 
 
Place: University of Tampere, Institute of Biomedical Technology, and School of 
Medicine, Fimlab laboratories, Department of Clinical Chemistry 
Author: Mäkelä, Kari-Matti Johannes 
Title: Applying genome-wide approach to define the genetics of low-density 
lipoprotein oxidation in two large cohorts 
Pages: 55 pp. 
Supervisors: Professor Terho Lehtimäki, Docent Csaba Ortutay 
Reviewers: Professor Terho Lehtimäki, Professor Matti Nykter 
Time: January 2013 
Abstract  
 
Background: Cardiovascular diseases (CVD) are the number one killer and cause of 
disability in today’s world. Oxidized low-density lipoprotein (oxLDL) is considered to be 
a key factor in the development of atherosclerosis which leads to CVD. The genetics of 
LDL oxidation are poorly known. 
Aims: In this work, I continued and extended our previously published genome-wide 
association study (GWAS) on oxLDL. Previously, single-nucleotide polymorphisms 
(SNP) were imputed to HapMap2 reference with 2.2 million variants. The aim of the 
present study was to find novel SNPs associated with oxLDL in a meta-analysis of two 
GWASs with SNPs imputed now to the 1000 genomes reference (ca. 20 million variants).  
Materials and Methods: GWASs were performed on a population of young healthy 
individuals (A: N=2,080, 45% male, aged 32±5 years, with the SNPTEST software), and 
in a patient sample (B: N=2,912, 69% male, 63±11 years, with the ProbABEL software), 
and a combined GWAS meta-analysis for cohort A and B data was carried out using the 
GWAMA software. Furthermore, the GWAS was run in the A population with top-SNP 
adjustment. 
Results: The genetic variant rs676210 (Pro2739Leu) in apolipoprotein B (apoB) was the 
only SNP independently associated with oxLDL (p=8.7 x 10
-168
) in the GWAS meta-
analysis. This is in accordance with our previously published study, and no new genome-
wide significant hits were found.   
Conclusions: No new oxLDL levels related SNPs were found in this study. The next step 
is to study the specific effects of rs676210 and its environmental factor interactions with 
cardiovascular endpoints more closely. 
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apoB apolipoprotein B 
BMI  body mass index 
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oxLDL  oxidized low-density lipoprotein 
PCI  percutaneous coronary intervention 
QQ   quantile quantile 
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Abbreviations are defined at first mention in the abstract and in the review of the 
literature and used only for concepts that occur more than twice.
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Introduction 
The number one killer and cause of disability in the world is cardiovascular diseases 
(Nabel, Braunwald 2012) caused by atherosclerosis (Libby, Ridker et al. 2011). 
Atherosclerosis is an inflammatory disorder that progresses slowly in the artery walls. As 
the blood flow in the arteries is disturbed—i.e. plaques rupture—severe clinical 
symptoms are observed (Davis, Donnan 2012). Oxidized low-density lipoprotein 
(oxLDL) is known to be an important factor in the pathogenesis of atherosclerosis 
(Ishigaki, Oka et al. 2009). 
The discovery of the human genome (Sachidanandam, Weissman et al. 2001) initiated 
an era of intense genetic studying and discoveries in the 21
st
 century. In 2002, the 
discovery of correlation between nearby genetic variations (Gabriel, Schaffner et al. 
2002) allowed the development of the HapMap database in 2005 (International HapMap 
Consortium 2005). High-throughput genotyping methods were developed (Hoheisel 
2006), allowing the inexpensive and rapid genotyping of multiple single-nucleotide 
polymorphisms (SNP). Furthermore, the development of the statistical methods needed in 
bioinformatics (Marchini, Howie 2010) and the power of modern computers allowed the 
first genome-wide association study to be conducted (Klein, Zeiss et al. 2005).  
Since then, hundreds of GWASs have been published (Manolio 2010)—not satisfying 
all the expectations (Manolio, Collins et al. 2009) but providing massive amounts of 
novel information on multiple common diseases (Hirschhorn, Gajdos 2011).  
In this thesis, I continued our previous work (Mäkelä, Seppälä et al. 2012). In the 
previous study, a genome-wide association study (GWAS) on oxidized low-density 
lipoprotein (oxLDL) was conducted with a single cohort with SNPs imputed to HapMap2. 
In the present study, the work is expanded by performing a meta-analysis of GWASes 
with two cohorts and using 1000-genomes-imputed SNPs. 
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Review of the literature 
 
The overall progress of the atherosclerotic process related to the genetics of oxidized LDL 
as based on the previous oxLDL GWAS (Mäkelä, Seppälä et al. 2012) is summarized in 
Figure 1. The concepts mentioned in the figure will be explained in the following 
sections.  
 
 
 
Figure 1. Oxidized LDL genetics in the intersection of inflammation and lipid metabolism of    the 
pathogenesis of atherosclerosis 
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1. Oxidized low-density lipoprotein (oxLDL) and 
atherosclerosis 
1.1 The journey of cholesterol and lipoproteins 
Atherosclerosis is a slowly progressing inflammatory disorder of the artery walls that can 
lead to coronary artery disease (CAD) and stroke (Lusis 2012). The pathogenesis of 
atherosclerosis is an extremely complex process affected by multiple biological pathways 
(Weber, Noels 2011).  
In this thesis, I focus mainly on the intersection of the lipoprotein metabolism and 
inflammation regarding the genetics of LDL oxidation (Figure 1). The cholesterol, which 
is acquired from food (and transported by chylomicrons to the liver) or produced by the 
liver itself, is packed into very-low-density-lipoprotein (VLDL) particles formed in the 
liver (Figure 2). An apolipoprotein-B-particle (apoB) is also formed and incorporated in 
the VLDL particle. The best-known function of apoB is to act as a ligand for LDL 
receptors in various cells (Ooi, Russell et al. 2012).  
VLDL is released to the bloodstream to transport cholesterol and various other 
substances into cells that require them. After interacting with HDL, or releasing some of 
the contents to tissues, VLDL becomes denser and turns into what is called intermediate-
density-lipoprotein (IDL) (Figure 2). After more of the contents are released, the particle 
becomes even denser, turning into low-density-lipoprotein (LDL). The apoB moiety is 
present in each of the particles.  
In normal lipoprotein metabolism, LDL is transported by the arteries to various tissues 
that require cholesterol and other contents of the particle for their function. After 
releasing the contents, the particle travels back to the liver where it is incorporated into 
hepatocytes by the LDL receptor and degraded (Yazdanyar, Jiang 2012). The liver creates 
new VLDL particles, and the journey starts again from the beginning.  
 
 10 
 
Figure 2. The highly complex nature of lipoprotein metabolism (Lusis, Pajukanta 2008) 
1.2 LDL oxidation and atherosclerotic plaque formation 
If certain conditions are met when LDL is travelling in the arteries, it can get lost on its 
way to the tissues and become stuck in the intima part of the arteries (Figure 1). These 
conditions include, for example, high shear stress, high blood pressure, diabetes, 
hypercholesterolemia, certain immunological signaling (Huo, Schober et al. 2003) by the 
endothelial cells covering the artery,  etc. (Nabel, Braunwald 2012). 
LDL cannot release itself from the intima (Kwon, Schroeder et al. 2008) and begins to 
be modified by its environment. Especially the apoB moiety is bound to the negatively 
charged extracellular matrix proteoglycans (Weber, Noels 2011). Reactive oxygen species 
and enzymes such as myeloperoxidase and lipoxygenases from inflammatory cells start 
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the oxidative modification of the LDL particle. When this foreign particle is noticed, the 
endothelial cells begin signaling that something is amiss. They express adhesion 
molecules and secrete chemokines to attract immune cells to the crime scene (Hansson, 
Hermansson 2011). Moreover, the displacement of platelet-derived chemokines drive the 
infiltration of the immune cells.  
As monocytes traveling in the bloodstream hear the call of the endothelial cells, they 
adhere to the adhesion molecules on top of the endothelial cells and start their signature 
movement called tethering and rolling (Woollard, Geissmann 2010). After this, the 
monocyte is firmly adhered to the endothelial surface by intercellular adhesion molecule 
1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) proteins. The monocyte 
then starts to move inside the artery wall by means of lateral transmigration and 
diapedesis between the endothelial cells.  
As the monocyte finds itself in a tissue (in this case, the intima of the artery) certain 
immunological signaling causes it to specialize into a macrophage. Normally, LDL is 
internalized to cells by so-called Brown-Goldstein LDL-receptor (Brown, Goldstein 
1983). Within this process is a mechanism that controls the internalization so that cells 
cannot get overfilled with LDL. However, as LDL is modified in the intima, it loses its 
typical form and turns into what is called oxidized LDL (oxLDL) (Ishigaki, Oka et al. 
2009). As macrophages specialize in cleaning up unfamiliar material from the body, they 
have a mechanism for recognizing the oxLDL particle, also called the scavenger receptor 
(Woollard, Geissmann 2010). The problem with this receptor is that it does not have a 
feedback mechanism that controls how much oxLDL has been incorporated into the 
macrophage (Figure 3). 
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Figure 3. The process of atherosclerosis that can take decades (Lusis 2012) 
As years go by and more and more LDL gets stuck in the intima, the macrophages 
become filled with the cholesterol delivered by the particles (Moore, Tabas 2011). A 
macrophage full of cholesterol is called a foam cell. Foam cells form the classical 
formation seen in histological staining of the arteries. As more and more foam cells are 
formed, they can be seen even with the naked eye on the artery wall (Nakashima, Fujii et 
al. 2007) and are called fatty streaks.  
When macrophages cannot fulfill their normal duties as they are filled with cholesterol, 
they start to die apoptotically (Seimon, Nadolski et al. 2010). The cholesterol (and other 
substances) begin to form the so-called necrotic core in the intima. As this material is 
foreign to the vessel wall, protective measures are launched. Smooth muscle cells from 
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the outer parts of the artery (adventitia) travel to the scene and start to form a so-called 
fibrous cap around the foreign material to sequestrate it from the environment (Lusis 
2012).  
The composition of the fibrous cap is known to be essential in determining how 
dangerous atherosclerosis is to an individual (Lusis 2012). A strong and thick fibrous cap 
is known to protect the foreign material securely and will not rupture easily. For some 
reason, some individuals form a thin fibrous cap. In these caps, the SMCs can be replaced 
with macrophages (Weber, Noels 2011).  
The process of atherosclerosis can already start in childhood. The formation of the 
atheromatous plaques with the fibrous cap can take 50 years (Nabel, Braunwald 2012). 
Atherosclerosis is a devious disease as it can go undetected all this time.  
The first clinical symptoms observed are usually severe chest pain that occurs if the 
atheromatous plaque interrupts the blood flow to the heart muscle (Nabel, Braunwald 
2012). Fortunately, modern medicine can usually treat these conditions easily with 
percutaneous coronary intervention (PCI).  
The most severe case is the rupture of a thinly capped atheromatous plaque (Figure 3). 
This kind of plaque can go undetected as it can be formed without disturbing the blood 
flow in the artery (Lusis 2012). Acute myocardial infarction caused by such plaques can 
be too severe to treat and a life is taken by sudden cardiac death. 
1.3 Methods for the measurement of LDL oxidation 
 
The lipoproteins are multi-molecular by nature (Lusis, Pajukanta 2008). They are formed 
by (i) a lipid core which contains fat-soluble substances such as cholesterol esters, 
triglycerides, vitamins, etc.; by (ii) a phospholipid bi-layer which forms the amphipathic 
surface of the particle separating the hydrophobic core from the hydrophilic environment; 
and by (iii) apo-lipoproteins which, e.g., guide the particles to the right places by acting as 
ligands for cell surface receptors (Figure 4). 
Due to the multi-molecular nature of LDL, oxLDL can be defined in multiple ways 
(Brinkley, Nicklas et al. 2009), and, therefore, multiple methods exist for its 
measurement. The different compartments can oxidize together or separately, and many 
metabolites that indicate LDL oxidation are also formed.  
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One of the most widely used method is the Mercodia oxLDL assay (Holvoet, Stassen et 
al. 1998). Figure 4 illustrates the principle of the assay. It measures the modification of 
the apoB moiety (Segrest, Jones et al. 2001) of LDL. When the LDL particle lies in the 
hostile environment of the artery intima, the lysine residues of apoB are substituted by 
aldehydes, which is recognized by the monoclonal 4E6 antibody of this enzyme-linked 
immunosorbent assay (ELISA).  
 
 
Figure 4. The principle of the Mercodia oxLDL assay. 
 
Of the other methods, LDL diene conjugation, for example, measures the oxidation of the 
lipid compartment of the LDL particle (Ahotupa, Marniemi et al. 1998). LDL baseline 
diene conjugation can be measured by determining the level of baseline diene
 
conjugation 
in lipids extracted from LDL. 
 
First, serum
 
LDL is isolated by means of precipitation with 
buffered heparin. Lipids
 
are then extracted from LDL samples with chloroform-methanol, 
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dried
 
under nitrogen, then redissolved in cyclohexane and analyzed
 
spectrophotometrically at 234 nm. 
It is extremely important to consider the limitations of the measurement method when 
interpreting the results.  
The Mercodia assay has been used in multiple studies; however, the results are 
inconclusive. Some studies show that oxLDL predicts cardiac syndromes (Meisinger, 
Baumert et al. 2005, Shimada, Mokuno et al. 2004, Tsimikas 2006), coronary artery 
disease (CAD) severity (Uzun, Zengin et al. 2004), plaque instability (Nishi, Itabe et al. 
2002), cerebral infarction (Uno, Kitazato et al. 2003), and restenosis (Naruko, Ueda et al. 
2006). However, some larger studies have been unable to replicate these results (Ishigaki, 
Oka et al. 2009).  
Interestingly, the removal of oxLDL has been shown to prevent atherosclerosis in mice 
(Ishigaki, Katagiri et al. 2008). 
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2. Genome-wide association study (GWAS) 
Since the discovery of the human genome (Sachidanandam, Weissman et al. 2001), the 
understanding of human genetics has taken huge leaps. In 2002, it was discovered that 
there is correlation between nearby genetic variations (Gabriel, Schaffner et al. 2002), and 
the HapMap database was developed in 2005 (International HapMap Consortium 2005). 
The idea of a genotyping microarray first came about in 1986 (Poustka, Pohl et al. 1986). 
Since then, microarray technology has seen huge advances (Hoheisel 2006), and 
inexpensive and rapid genotyping of multiple single-nucleotide polymorphisms (SNP) has 
become available to a wide audience. Moreover, excellent statistical methods in 
bioinformatics have been developed (Marchini, Howie 2010), allowing the first genome-
wide association study to be performed (Klein, Zeiss et al. 2005).  
To date, hundreds of GWASs have been published (Manolio 2010). The GWAS 
method has its problems (Manolio, Collins et al. 2009), but the approach has facilitated 
the location of hundreds of novel complex disease-associated loci in the human genome 
(Hirschhorn, Gajdos 2011)—the most recent being the extensive GWAS on CAD 
(CARDIoGRAMplusC4D Consortium, Deloukas et al. 2012) (Figure 5). 
The theory behind a GWAS is the so-called common disease–common variant 
hypothesis (Manolio, Brooks et al. 2008). It postulates that individuals are predisposed to 
complex diseases by carrying many varied alleles with small independent effect but with 
a large combined effect, ultimately manifesting as, e.g., coronary artery disease. In a 
GWAS, the idea is to harvest these areas in studies with thousands of individuals to find 
all the small variations in the genome that impose a higher risk of the studied disease. 
The main critique towards GWASs (McClellan, King 2010) comes from the 
evolutionary perspective: the rare and harmful mutations have been removed during many 
generations (Barreiro, Laval et al. 2008). The majority of the variation in the human 
genome is quite recent. Moreover, the majority of GWAS findings are on so-called gene 
deserts where there is no known mechanism of function. Furthermore, the inability to find 
a plausible biological explanation to the associations compels McClellan to infer that the 
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majority of the findings could be spurious mostly due to unaccounted population 
stratification (McClellan, King 2010).  
However, GWASs are planned so that they tag the most probable areas with an 
association to the studied phenotype (Klein, Xu et al. 2010, Wang, Bucan et al. 2010). 
This is a built-in feature of the technique, because it takes advantage of the linkage 
disequilibrium (LD) of the human genome. It was discovered in the early 21st century 
that the genome is most likely structured so that large LD blocks are passed down through 
the generations (Gabriel, Schaffner et al. 2002). This means that nearby single-nucleotide 
polymorphisms (SNPs) are highly correlated with each other. The genotyping arrays were 
therefore designed to capture the variation in the genome by taking one tag from each of 
these blocks. It is thus not possible to find the exact spot behind the association, merely 
the most probable area. Hence, further studies are required to pinpoint the mechanism 
behind the associations.  
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Figure 5. Findings of recent coronary artery disease (CAD) GWASs (CARDIoGRAMplusC4D 
Consortium, Deloukas et al. 2012, Lusis 2012) 
To explain why most associations are found in gene deserts, there could be a yet unknown 
mechanism underlying such associations (Klein, Xu et al. 2010, Wang, Bucan et al. 
2010). Moreover, more gene-gene and gene-environment interaction studies will be 
needed to determine where the elusive heritability lies (Zuk, Hechter et al. 2012). 
So far, GWASs have been a success story, bringing about vast collaborative projects 
worldwide to illuminate the largely unknown mechanisms behind complex diseases. The 
major challenge is translating this knowledge into clinical practice (Fugger, McVean et al. 
2012).  
Hundreds of loci are known to be involved in lipoprotein metabolism (Lusis, Pajukanta 
2008) and the pathogenesis of atherosclerosis (Lusis, Fogelman et al. 2004, Lusis, 
Fogelman et al. 2004). Large GWASs have been conducted to detect multiple new loci 
associated with CAD (Schunkert, Konig et al. 2011, CARDIoGRAMplusC4D 
Consortium, Deloukas et al. 2012) and lipid metabolism (Teslovich, Musunuru et al. 
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2010, Willer, Sanna et al. 2008). Moreover, the availability of next-generation sequencing 
in the near future will bring about immense amounts of additional information (Shendure, 
Ji 2008). 
One possibility would be to utilize GWAS results in genetics testing (Grosse, Khoury 
2006). Attempts have been made to use GWAS results in predicting disease 
susceptibility, but this objective has been elusive in practice (Ripatti, Tikkanen et al. 
2010). A second avenue is to find out whether the GWAS-tagged regions could be 
utilized as intervention targets (Fugger, McVean et al. 2012). 
2.1 Genetics of LDL oxidation 
Even though more and more genetic studies are published every day, the genetic variation 
affecting LDL oxidation is mostly unknown. We published the first GWAS on oxLDL, 
discovering one SNP highly associated with serum oxLDL levels (Mäkelä, Seppälä et al. 
2012). We found one SNP in the apoB locus that causes a missense mutation in the apoB 
particle (Figure 1). The goal of the present thesis is to determine whether further loci 
could be defined with more advanced bioinformatic methods.  
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Objectives 
The specific aims of this study were 
 
1. To expand a previously conducted GWAS (Mäkelä, Seppälä et al. 2012) by 
means of a GWAS meta-analysis of two large cohorts imputed to the broader 
1000 genomes reference genome to find additional genetic variation affecting 
to the oxidation of serum LDL 
 
2. To verify whether any new information was acquired by running the GWAS 
again by adjusting for the top SNP (rs676210) found in the previous study by 
using conditional analysis method (Mäkelä, Seppälä et al. 2012) 
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Materials and methods 
1. Study populations and ethical statements 
The Cardiovascular Risk in Young Finns Study (YFS) 
 
YFS is a longitudinal Finnish population sample for studying cardiovascular risk factors 
and the evolution cardiovascular diseases from childhood to adulthood (Raitakari, Juonala 
et al. 2008). The first cross-sectional study was conducted in  1980 at five centers 
(Tampere, Helsinki, Turku, Oulu, and Kuopio). A total of 3,596 subjects in the age 
groups of 3, 6, 9, 12, 15, and 18 were selected randomly from the national population 
register.   
The subjects have been re-examined as adolescents in 1983 and 1986 and as adults in 
2001, 2007, and 2012. In the present study, the data from 2001 was used. 
In 2001, a total of 2,283 participants aged from 24 to 39 years were examined for 
numerous study variables (Raitakari, Juonala et al. 2008). Mainly the measurement of 
oxLDL was used in the current study. Genotype and phenotype data were available for 
2,080 subjects, and they formed the present study population.  
 
 
The Ludwigshafen Risk and Cardiovascular Health  (LURIC) study 
 
The LURIC study consists of 3,316 Caucasian patients who were referred to coronary 
angiography due to chest pain at a tertiary care center in Southwest Germany between 
1997 and 2000 (Winkelmann, März et al. 2001). 
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All the necessary covariate and endpoint data (genotyping and oxLDL-measurement) 
were available for 2,912 LURIC patients. They formed the present study population. 
 
 
Ethical statements 
 
Both studies (YFS and LURIC) were conducted according to the guidelines of the 
Declaration of Helsinki. The study protocols were approved by local ethics committees. 
All participants gave an informed consent. 
2. Clinical and biochemical characteristics of the study 
cohorts 
In both studies, the circulating oxLDL levels were measured with the same competitive 
enzyme-linked immunosorbent assay (ELISA) utilizing a specific murine monoclonal 
antibody, mAB 4E6 (Holvoet, Stassen et al. 1998) (Mercodia, Uppsala, Sweden; 
detection limit < 0.3 U/l). 
The assay utilizes the phenomenon where a conformational epitope is formed at the 
apoB moiety of LDL when at least 60 lysine residues are substituted with aldehydes while 
the LDL is oxidized (Figure 4). Moreover, aldehydes released from activated platelets or 
the endothelial cells under oxidative stress may also induce the modification of apoB 
(Paniagua, Lopez-Miranda et al. 2005).    
In both studies, venous blood samples were drawn after an overnight fast. In YFS, 
standard methods were used for the determination of serum total cholesterol, 
triglycerides, and high-density lipoprotein (HDL) cholesterol. LDL cholesterol was 
calculated in  YFS by the Friedewald formula:  LDL cholesterol = total cholesterol – 
HDL cholesterol – triglyceride-concentration / 2.2 (Friedewald, Levy et al. 1972). In 
LURIC, lipoproteins were separated by means of a combined ultracentrifugation–
precipitation method (ß-quantification) (Winkelmann, März et al. 2001).  
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In YFS, for ApoB analysis a immunoturbidometrical assay was used (Orion 
Diagnostica, Espoo, Finland); the interassay CV was 2.8% for apoB (Juonala, Viikari et 
al. 2008). In LURIC, apoB was analyzed by means of a photometric assay which uses 
antihuman apoB antibody (apoB Test, Rolf Greiner Bio-chemica, Flacht, Germany). 
In both studies, the formula body-mass index (BMI) = weight (kg) / height (m)
 2  
was 
used for BMI calculation. 
3. Genotyping and quality control 
The YFS employed a custom-built Illumina Human 670k BeadChip for genotyping at the 
Welcome Trust Sanger Institute. Peripheral blood leukocytes were used for the extraction 
of genomic DNA. A commercially available kit and Qiagen BioRobot M48 Workstation 
were used according to the manufacturer’s instructions (Qiagen, Hilden, Germany). 
Genotype calling was carried out with the Illuminus clustering algorithm. Following the 
Sanger genotyping pipeline quality control (QC) criteria (duplicated samples, 
heterozygosity, Sequenom fingerprint discrepancy, or low call rate), 56 samples failed to 
meet the criteria. From the remaining 2,500 samples, 3 were removed due to low call rate 
(<0.95), 54 were excluded because of possible relatedness (pi-hat > 0.2), and one subject 
failed gender check. The Hardy–Weinberg equilibrium (HWE) test excluded 11,766 
SNPs (p ≤ 10-6), and 7,746 SNPs failed the missingness test (call rate < 0.95). A further 
34,596 SNPs failed the frequency test (MAF < 0.01). After QC, 2,442 samples with 
546,677 genotyped SNPs were available for the GWAS analysis.  
The imputation of SNPs refers to using the LD structure of the genome in the 
prediction of the SNPs that have not been genotyped (Marchini, Howie 2010). Genotype 
imputation was performed in the earlier study (Mäkelä, Seppälä et al. 2012) using MACH 
1.0 (Li, Willer et al. 2010) and HapMap II CEU (release 22, NCBI build 36, dbSNP 126) 
samples as a reference. After imputation, 2,543,887 SNPs were available. SNPs with a 
squared correlation (r
2
) of < 0.30 between imputed and true genotypes were eliminated 
from the analysis. Palindromic A/T and C/G SNPs were removed before imputation. 
After imputation, 2,543,887 SNPs were available.  
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In this study, to get more SNPs for analysis, genotype imputation was performed using 
IMPUTE2 and 1000 Genomes Interim Phase I EUR July 2011 haplotypes as a reference. 
SNPs with info ≥ 0.4 were considered well imputed. After imputation, more than 10 
million SNPs were available for analysis. 
Genomic DNA was prepared from EDTA anticoagulated peripheral blood by means of 
a common salting-out procedure in LURIC. The Affymetrix Genome-Wide Human SNP 
Array 6.0, and the Affymetrix Mapping 500K Array were used for genotyping. The 
following QC criteria were applied: individual call rate < 0.95, SNP call rate < 0.98, 
HWE p value < 10
-4
, and MAF < 0.01. Genotype imputation was completed with MACH 
1.0 (Li, Willer et al. 2010) and 1000 Genomes Pilot + HapMap 3 release 2 samples as a 
reference. SNPs with a squared correlation of ≥ 0.30 between imputed and true genotypes 
were considered well imputed. Both genotype and clinical data were available for 2,912 
samples in the present study. 
4. Performing the GWAS and the meta-analysis 
4.1 Data preparation for statistical analysis 
I had the data from both cohorts available on my standard desktop computer (Dell 
Optiplex 780). The data consists of three parts: (i) the phenotypic data, (ii) the genotypic 
SNP data, and (iii) the imputed SNP data. I used R Statistical package v. 2.11.1 
(http://www.r-project.org) for reading in the phenotypic data of both cohorts in separate 
files (Code 1). 
 
 
a <-read.table("YFS_data.dat"  ,header=T,sep="\t",comment="",quote="") 
b <-read.table("LURIC_data.dat",header=T,sep="\t",comment="",quote="") 
 
 
Code 1 – R-code for reading the data files 
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The required variables were selected from the data files (oxLDL, age, sex, BMI, and 
apoB). Principal components were also included and used to control for population 
stratification (Price, Patterson et al. 2006). The oxLDL measurement was transformed 
close to normal with inverse normal transformation. To get one variable for the GWAS 
analysis, a linear regression model was used with Y=oxLDL as well as age, sex, BMI, and 
principal components as covariates. The standardized residuals (mean 0, s.d. 1) obtained 
from this linear regression model were applied as the endpoint in the GWAS calculations 
in both cohorts. (Code 2) 
 
 
# select the needed data 
d <- a[c("study_ID", "oxldl", "age", "sex", "apoB")] 
d <- na.omit(d) 
 
# load the precalculated principal components 
principal_components <- read.table("mds.dat", header=T) 
 
d <- merge(d, principal_components, by=1, all=F, sort=F) 
 
# normal transform the oxLDL variable 
d["oxldltrC"]  <- qqnorm(d["oxldl"][,], plot.it = F)$x 
 
# with the linear regression model and obtain residuals for the GWAS 
d_lm <- lm(d$oxldltrC ~ d$sex + d$age+ d$bmi+ d$C1 + d$C11+ d$C15 ) 
d$oxldltrC_res <- residuals(d_lm) 
 
Code 2 – R-code for preparing the data for GWAS 
The data was saved and the standard GWAS software used for the calculations during 
next steps. The GWAS with top-SNP adjustment in YFS was performed identically, with 
the exception of adding rs676210 as a covariate before extracting the residuals. 
4.2 Individual GWAS analyses 
Because of the differences in the format of the genotypic and imputed data, the  
SNPTEST software was used for the YFS data and the ProbABEL software for the 
LURIC data. Both pieces of software fit a linear regression model (Figure 6) for each 
genotyped and imputed SNP and print out the result in the result file for each SNP 
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separately. Genotypes were coded as 0, 1, or 2 when the SNP was genotyped, and by 
dosage (scale 0–2) when imputed. SNPTEST and ProbABEL take in to account the 
uncertainty of imputation with the imputed SNPs. 
 
 
Figure 6. Linear regression in ProbABEL (Aulchenko, Struchalin et al. 2010). 
An SSH connection was created to a separate UNIX environment that utilizes a high-
performance computer cluster for the calculations. The phenotypic, genotypic SNPs, and 
imputed SNPs data were uploaded to the server.  
 
For YFS, a separate process for each chromosome was initiated for the SNPTEST 
software. For LURIC, similarly, a separate process was initiated for each chromosome 
utilizing the ProbABEL software. (Code 3) 
 
 
grun -n oxldlC_1 snptest -data yfs_1000g_data.bgen oxldlC.sample -
frequentist 1 -method expected -pheno oxldlC -nowarn -o 
oxldlC_chr1.txt 
 
grun -n ab_oxldl_1_chr1 -mem 8G palinear --info 
luric_1000g_data_chr1.mlinfo --dose luric_1000g_data_chr1.mldose --
pheno abel_oxldl_luric.phe --out oxldl_chr1 
 
 
Code 3 – UNIX commands for creating processes for the two programs on chromosome 1. 
Similarly, the commands are run for chromosomes 2–22.  
4.3 Extracting and combining the results for meta-analysis 
Both ProbABEL and SNPTEST output result in separate result files for each 
chromosome. The next step is to combine the results into one file.  
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For ProbABEL, an R script was used (Code 4). It loops through each chromosome 
result file and picks the variables needed for the figure drawing and meta-analysis. 
Similarly, the results of SNPTEST were incorporated into one file.  
Once the results were in a single file, QQ and Manhattan plots were drawn of the 
results for both cohorts separately. R script was used for the drawing. For the QQ plot, the 
p value for each SNP is plotted together with the expected distribution to see if there is 
any deviation from normal distribution. In the Manhattan plot, the p value of each SNP is 
plotted on a chromosome map to see where the associations come from. SNPs that 
associated with oxLDL with an a priori set Bonferroni-corrected p value < 5 x 10 
-8
 were 
marked on the figures to see whether there were statistically significant associations 
(Figure 7).  
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#read and process ProbABEL results for each chromosome 1-22 
for (i in 1:22) { 
 
    filename <- paste(out_path, trait, "_chr", i, "_add.out.txt", 
sep="") 
    if (file.access(filename, mode = 0) == -1) { 
      msg(paste("ProbABEL: No such file", filename)) 
      next 
    } 
     
    msg(paste("ProbABEL: Reading file", filename)) 
    x <- read.table(filename, header=T, na.strings="NA", as.is=T) 
    names(x)[match("name", names(x))] <- "SNP" 
 
    # Base position for the imputed data 
      filename <- paste(luric_path, 
"1000g_pilot/1000g_pilot_liftover_chr",i,".txt", sep="") 
      msg(paste("Reading file", filename)) 
      hg19 <- read.table(filename, header=T, as.is=T, quote="", 
comment="", sep="\t") 
      names(hg19) = 
c("CHR","HG18_POS","HG19_POS","HG18_NAME","HG19_NAME","HG19_SNPID","GEN
E") 
 
      x <- cbind(x["HG19_NAME"],x["HG19_SNPID"], x["CHR"], 
x["HG19_POS"], x["AA1"], x["AA2"], "STRAND" = "+", x["MAF"], x["n"], 
x["beta2"], x["sebeta_SNP_add"], x["p"], x["Rsq"], x["Quality"], 
"IMPUTED" = 1) 
 
 
    # Sort by CHR and BP for Manhattan plot 
    xy <- xy[order(xy$CHR, xy$BP, na.last=NA, decreasing=F), ] 
     
    msg(paste("Writing file", out_filename)) 
    write.table(meta, out_filename, append=app_flag, 
col.names=!app_flag, row.names=F, sep ="\t",  quote=F, na=out_na, 
dec=out_dec) 
 
} 
 
Code 4 – R script for processing the output of ProbABEL. Similar code was used for SNPTEST 
output.  
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4.4 Meta-analysis 
In the meta-analysis, the results of the two GWASs are summarized. This was 
accomplished with GWAMA software (Magi, Morris 2010), which accepts the result files 
of ProbABEL and SNPTEST. GWAMA calculates the summary of the association for 
each SNP that is found in both cohorts with fixed-effects meta-analysis.  
 
 
pheno=$1 
 
echo "Step 1/3: Writing $pheno".in" file" 
echo $pheno"_yfs.txt" > $pheno".in" 
echo $pheno"_luric.txt" >> $pheno".in" 
 
echo "Step 2/3: Running fixed effects meta-analysis for $pheno" 
GWAMA -i $pheno".in" -o $pheno"_fixed" -gc -qt 
 
echo "Step 3/3: Sorting results and picking top hits from fixed effects 
results" 
head -1 $pheno"_fixed.out" > $pheno"_fixed_sort.out" 
tail +2 $pheno"_fixed.out" | sort -nk 10 >> $pheno"_fixed_sort.out" 
head -1000 $pheno"_fixed_sort.out" > $pheno"_fixed_top.txt" 
rm $pheno"_fixed_sort.out" 
 
 
Code 5 – The GWAMA meta-analysis shell script for UNIX 
Similarly to the individual GWASs, QQ and Manhattan plots were drawn. Moreover, 
regions harboring association signals were visualized using LocusZoom (Pruim, Welch et 
al. 2010). 
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Results 
1. GWASs in YFS and LURIC 
The YFS and LURIC cohorts are quite different, since YFS is a population sample and 
LURIC a patient sample. Moreover, there was a female predominance in YFS, while the 
patients in LURIC were predominantly male (Table 1). Furthermore, there were age 
differences between the cohorts, with YFS as the younger and LURIC as the older 
population. The mean oxLDL levels also varied, being higher in YFS and lower in 
LURIC (Table 1).  
 
Table 1. General characteristics of the study populations.  
Study Acronym n* Age, 
years† 
% Male OxLDL (U/l) † 
The Cardiovascular Risk in 
Young Finns Study 
YFS 2080 31.7 
(5.0) 
45.2% 83.4 (25.1) 
The Ludwigshafen Risk and 
Cardiovascular Health Study 
LURIC 2912 62.6 
(10.7) 
69.3% 75.0 (28.3) 
 
Abbreviations: n, number. *n for subjects having data required for the present study; 
†values expressed as means (standard deviations). 
 
 
The GWAS results from YFS and LURIC are presented in Figure 7.  
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Figure 7.  QQ and manhattan plots for the Young Finns Study (YFS) and the Ludwigshafen Risk 
and Cardiovascular Health (LURIC) study 
In the quartile-quartile (QQ) plot, the gray line represents normal distribution and the p 
values of the GWAS SNPs are plotted on the y-axis. It shows a clear deviance from 
normal distribution with the GWAS results. This means that the results are most probably 
not due to chance.    
The Manhattan plot maps the SNP p values on chromosomes. On the x-axis is the 
chromosome number (1-22), and the y-axis shows the –log of the association p value. On 
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the Manhattan plots, it is clearly shown that the results are similar in YFS and LURIC. 
The significant associations are found on chromosome two.  
2. Meta-analysis of the GWAS results 
In the meta-analysis, we confirmed the strong association in the chromosome two region 
(Figure 8, Supplementary Table 1). A total of 635 SNPs were associated with oxLDL 
with genome-wide statistical significance (P < 5 x 10
-8
).  
 
Figure 8. The meta-analysis results. 
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The panels B and C in Figure 8 show similar results as those found in the individual 
GWASs. The A panel shows a zoom-in in the main association region in chromosome 2. 
On the y-axis is the –log p value of the SNPs. The gray line represents the recombination 
rate on the chromosome (the approximated LD blocks). The panel shows genes in the 
region.  
All of the SNPs were on the apolipoprotein B-100 precursor coding region (OMIM 
107730) on chromosome 2.  
 
3. Top SNP adjustment 
I also ran the GWAS for YFS with top SNP adjustment (Figure 9). There were no new 
associations in addition to the previously published one. This probably means that all of 
the 635 SNPs are correlated with rs676210 (due to linkage disequilibrium) so that the 
strong association of rs676210 with oxLDL also shows a false association with the other 
SNPs.  
These results confirm that the strongest association with oxLDL is most probably due 
to rs676210. A larger population could be needed to find possible further associations.  
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Figure 9. No further associations at p < 5x10-8 after running the GWAS with top SNP adjustment in 
the YFS 
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Discussion 
I performed a GWAS meta-analysis on oxLDL in two large cohorts and confirmed a 
previously found APOB locus on chromosome two to be associated with oxLDL. Of the 
hundreds of SNPs associated with circulating oxLDL levels in a healthy Caucasian adult 
population (YFS) and a patient population (LURIC), only one missense mutation leading 
to a proline-to-leucine interchange in ApoB (rs676210) on chromosome two remained 
significant in further analysis. This result is in accordance with our previously published 
study (Mäkelä, Seppälä et al. 2012) and, unfortunately, no new genome-wide significant 
loci were found. 
1. The GWAS results 
The differences in the measurement of oxLDL could affect the results. There were 
differences in the mean oxLDL levels of the respective study cohorts even though the 
same assay was used. This could be due to levels of oxidants or anti-oxidants, different 
storage conditions, or differences in the use of statin medication (Ky, Burke et al. 2008). 
In LURIC, there was a higher proportion of statin users in comparison to the healthier 
YFS population. However, the GWAS results were parallel in spite of the differences.   
The meta-analysis results and the additional rs676210-conditioned analysis confirmed 
the association of rs676210 with oxLDL in these two cohorts.  
ApoB is coded by the gene apolipoprotein B-100 precursor coding region (OMIM 
107730) on chromosome two. The top SNP, rs676210, causes a Proline -> Leucine 
missense mutation in the apoB protein.  
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2. Genetics of LDL oxidation 
There are few previous reports about the genetics of LDL oxidation. The interleukin-1b 
(IL-1B) gene has been associated with oxLDL levels (Manica-Cattani, Medeiros Frescura 
Duarte et al. 2012), supporting the role of genetic variation in LDL oxidation. To our 
knowledge, ours was the first GWAS on circulating oxLDL (Mäkelä, Seppälä et al. 
2012). In our study, rs676210 association was confirmed by employing a forward 
selection algorithm, performing haplotype analyses, assessing the damage-producing 
probability of the SNPs, and running the GWAS with top-SNP adjustment. 
There are a few other studies related to the genetic variant rs676210. In a large lipid 
GWAS, the rs676210 minor allele (A) was associated with lower triglyceride, total 
cholesterol, and LDL cholesterol levels, and with higher HDL cholesterol levels 
(Teslovich, Musunuru et al. 2010). Furthermore, rs676210 has been found to associate 
with triglycerides, VLDL-related fractions, and mean VLDL/LDL size (Chasman, Pare et 
al. 2009). In addition, rs676210 has been linked to an improved response to fenofibrate 
treatment (Wojczynski, Gao et al. 2010). The treatment was reported to lower triglyceride 
levels by 24.7%, 28.3%, and 34.5% according to the rs676210 genotypes GG, GA, and 
AA, respectively. Fenofibrates have been shown to have effect on oxLDL (Hogue, 
Lamarche et al. 2008).  
The reason why rs676210 associates with oxLDL could the that the missense mutation 
in apoB (Kumar, Butcher et al. 2011) makes LDL more prone to oxidation in the intima 
of the arteries. The atherosclerotic process involves hundreds of genes with which LDL 
interacts (Figure 10). For example, the mutation could cause the apoB moiety to change 
the 3D structure so that LDL is more easily stuck in the proteoglycans in the matrix of the 
intima (Weber, Noels 2011). Therefore, the LDL particle could be exposed to the 
oxidative processes longer.  
We have now tagged one locus with LDL oxidation. This association requires 
extensive further study to determine the more specific effects of rs676210 (Fugger, 
McVean et al. 2012). 
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Figure 10. The genes involved in atherosclerosis (Lusis, Fogelman et al. 2004) 
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3. Limitations and strengths of the study 
The main reason for not finding additional signals could be the small number of study 
subjects. In the largest GWASs, hundreds of thousands of individuals are required to 
significantly find the weakest signals. 
The two cohorts used are also quite heterogenic, which could dampen the weaker 
signals (Han, Eskin 2012). Moreover, the analysis was performed only with Caucasian 
subjects and cannot be generalized to other populations.  
Furthermore, a meta-analysis of the top-SNP-adjusted GWAS was not done. However, 
there most probably would not have been additional signals.  
The oxLDL was measured with a method that only takes in to account the changes in 
the apoB protein part of the LDL particle. This does not provide a comprehensive view of 
LDL oxidation, and further studies with different measurements of LDL oxidation should 
be conducted. 
The greatest strength of the study is the replication of the major results in two 
independent cohorts. Furthermore, the quality control before the GWAS was carried out 
rigorously.  
 There were significant differences in sex distributions and mean ages between the 
cohorts. However, the association of rs676210 with oxLDL concentration remained 
significant in spite of these and other differences in the background populations.  
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4. Future directions 
It is hypothesized that the elusive heritability could be hidden in gene–environment 
interactions (Manolio, Collins et al. 2009). It is also known that multiple modifiable risk 
factors increase the risk of cardiovascular events. Major of such risk factors are, e.g., 
smoking (Pipe, Papadakis et al. 2010), diet, exercise, hypertension, diabetes, and obesity 
(Nabel, Braunwald 2012). The next step could be to study whether rs676210 acts 
differently in smokers and non-smokers (Kassi, Dalamaga et al. 2009) or with other 
oxidation related environmental factors. 
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Summary and conclusions 
 
The main findings and conclusions were 
 
1. I successfully expanded the previously conducted GWAS (Mäkelä, Seppälä et al. 
2012) by GWAS meta-analysis in two large cohorts imputed to 1000 genomes 
reference genome. The previously significantly associated locus on chromosome 
two was replicated in this study.  
 
2. The GWAS was run again by adjusting for the top-SNP in the previous GWAS 
(rs676210) to verify whether any new SNPs were found. Unfortunately rs676210 
remained the only SNP independently associated with serum oxLDL. 
 
 
The present findings support our previous findings, and no novel associations were 
found. The missense mutation (Pro2739Leu, rs676210) causing a proline-to-leucine 
interchange in apoB seems to influence LDL oxidation in a stepwise manner. The next 
step is to further clarify the mechanism behind the association by studying, for example, 
whether the SNP acts differently in smokers and non-smokers with cardiovascular 
endpoints.  
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Supplementary Data 
Table 2. The single-nucleotide polymorphisms (SNP) found in the meta-analysis. All 
of the SNPs were on and near the apolipoprotein B-100 precursor coding region (OMIM 
107730) on chromosome 2 (except for rs4781086 on chromosome 16; it did not, however, 
remain significant in further analyses).  
 
rs-number 
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osome position p value 
 
rs-number 
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e position p value 
rs673548 2 21237544 7.25E-168 
 
rs538928 2 21389019 1.10E-16 
rs676210 2 21231524 8.67E-168 
 
rs559967 2 21395598 1.10E-16 
rs2678379 2 21226560 1.40E-167 
 
rs477146 2 21396334 1.10E-16 
rs1042034 2 21225281 2.76E-167 
 
rs312983 2 21378580 1.11E-16 
rs4665710 2 21221035 1.03E-166 
 
rs522250 2 21387113 1.11E-16 
rs7557067 2 21208211 5.72E-158 
 
rs563696 2 21389430 1.11E-16 
rs6544366 2 21204025 6.68E-158 
 
rs312985 2 21378805 1.12E-16 
rs10184054 2 21203877 7.43E-158 
 
rs529396 2 21381268 1.13E-16 
rs4564803 2 21205502 8.38E-158 
 
rs530474 2 21381435 1.13E-16 
rs6754295 2 21206183 1.93E-157 
 
rs554414 2 21394892 1.13E-16 
rs11902417 2 21198900 2.55E-157 
 
rs556504 2 21395261 1.13E-16 
rs6728178 2 21193946 8.06E-157 
 
rs559318 2 21381490 1.14E-16 
rs6711016 2 21123352 7.73E-129 
 
rs532300 2 21381608 1.14E-16 
rs56296027 2 21134011 7.86E-128 
 
rs533211 2 21381702 1.14E-16 
rs78980904 2 21121464 7.51E-121 
 
rs560522 2 21382363 1.14E-16 
rs11680233 2 21240031 5.58E-113 
 
rs527034 2 21382786 1.14E-16 
rs11126598 2 21240364 1.53E-109 
 
rs553523 2 21394798 1.14E-16 
rs3791980 2 21245329 9.52E-107 
 
rs479545 2 21389897 1.16E-16 
rs4296389 2 21142994 5.27E-100 
 
rs493404 2 21394340 1.16E-16 
rs3923037 2 21148274 2.37E-87 
 
rs549959 2 21394458 1.16E-16 
rs6732011 2 21146521 2.91E-87 
 
rs496100 2 21394614 1.16E-16 
rs10180633 2 21144829 3.94E-87 
 
rs492494 2 21394248 1.17E-16 
rs4426495 2 21143982 4.54E-87 
 
rs490757 2 21388224 1.18E-16 
rs10183548 2 21145499 9.16E-87 
 
rs578864 2 21393937 1.18E-16 
rs1318005 2 21214208 1.23E-58 
 
rs492365 2 21394201 1.18E-16 
rs1318006 2 21214152 1.29E-58 
 
rs488507 2 21393689 1.19E-16 
rs4665642 2 21213185 1.89E-58 
 
rs492364 2 21394199 1.21E-16 
rs6722374 2 21213062 1.99E-58 
 
rs538862 2 21404980 1.23E-16 
rs1320143 2 21212348 4.29E-58 
 
rs12997242 2 21381177 1.25E-16 
rs1318004 2 21214209 7.51E-58 
 
rs484268 2 21406471 1.26E-16 
rs10495713 2 21200519 6.87E-56 
 
rs499560 2 21404398 1.27E-16 
rs34335269 2 21196250 8.30E-56 
 
rs312984 2 21378778 1.28E-16 
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rs473770 2 21403965 1.28E-16 
rs6733447 2 21198136 9.09E-56 
 
rs507627 2 21403829 1.29E-16 
rs56403064 2 21206906 9.17E-56 
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rs7571469 2 21204481 1.06E-55 
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rs1320145 2 21192362 1.94E-55 
 
rs537810 2 21404816 1.31E-16 
rs17041662 2 21189068 4.07E-55 
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rs4665790 2 21188570 4.18E-55 
 
rs567071 2 21405790 1.32E-16 
rs1320144 2 21192112 4.98E-55 
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rs6721844 2 21212571 1.31E-54 
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rs4665639 2 21186891 1.53E-54 
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rs17041663 2 21190238 4.79E-54 
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rs312936 2 21408647 1.41E-16 
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rs1712249 2 21385974 1.42E-16 
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rs561850 2 21395805 1.42E-16 
rs56327713 2 21206836 3.39E-52 
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rs475887 2 21389485 1.56E-16 
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rs312975 2 21374535 1.85E-51 
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rs312938 2 21409165 2.08E-16 
rs312978 2 21376584 2.20E-51 
 
rs312940 2 21409717 2.16E-16 
rs312949 2 21334283 2.28E-51 
 
rs938848 2 21196847 2.28E-16 
rs312977 2 21376312 3.29E-51 
 
rs484399 2 21406568 2.28E-16 
rs6707950 2 21187641 4.89E-51 
 
rs62120843 2 21196684 2.30E-16 
rs312950 2 21336222 5.83E-51 
 
rs10495712 2 21196112 2.40E-16 
rs6705668 2 21142546 1.24E-50 
 
rs62120842 2 21196447 2.43E-16 
rs4274565 2 21141909 3.75E-50 
 
rs544039 2 21398985 2.44E-16 
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rs4356624 2 21141488 4.65E-50 
 
rs499757 2 21404468 2.59E-16 
rs312952 2 21337857 4.96E-50 
 
rs4490138 2 21125165 3.30E-16 
rs312951 2 21337403 4.99E-50 
 
rs17397667 2 21184847 3.31E-16 
rs2337382 2 21184764 1.14E-49 
 
rs528114 2 21382623 3.70E-16 
rs11693076 2 21140033 1.24E-49 
 
rs524455 2 21415728 3.79E-16 
rs4606879 2 21138868 1.03E-48 
 
rs2337381 2 21186121 4.35E-16 
rs11903024 2 21138740 1.06E-48 
 
rs68093099 2 21190107 4.52E-16 
rs7604788 2 21190024 3.47E-45 
 
rs62120837 2 21187371 4.74E-16 
rs557624 2 21398080 4.63E-45 
 
rs62120838 2 21187513 4.80E-16 
rs588245 2 21270057 4.52E-44 
 
rs4665788 2 21188488 5.05E-16 
rs523095 2 21387193 8.55E-44 
 
rs1801695 2 21224853 5.11E-16 
rs552658 2 21388146 9.32E-44 
 
rs62120847 2 21205920 5.33E-16 
rs4533439 2 21141815 1.04E-43 
 
rs56142315 2 21189383 5.48E-16 
rs564539 2 21389505 1.08E-43 
 
rs535713 2 21414072 5.55E-16 
rs6755762 2 21141323 1.12E-43 
 
rs503662 2 21414142 5.76E-16 
rs565394 2 21405589 1.94E-43 
 
rs614303 2 21313577 6.66E-16 
rs661665 2 21265141 2.09E-43 
 
rs13002939 2 21120901 6.93E-16 
rs536854 2 21404717 2.48E-43 
 
rs569014 2 21415763 7.74E-16 
rs510894 2 21407010 3.06E-43 
 
rs527259 2 21416019 8.28E-16 
rs554871 2 21403017 3.43E-43 
 
rs312052 2 21428185 9.31E-16 
rs491752 2 21400765 4.49E-43 
 
rs539845 2 21416614 1.01E-15 
rs477978 2 21396406 6.28E-43 
 
rs312053 2 21428049 1.09E-15 
rs500195 2 21396433 6.29E-43 
 
rs577584 2 21299867 1.18E-15 
rs577072 2 21393723 7.15E-43 
 
rs4596008 2 21417576 1.21E-15 
rs312941 2 21410347 9.52E-43 
 
rs36047821 2 21418719 1.42E-15 
rs533617 2 21233972 1.19E-42 
 
rs34125138 2 21418756 1.44E-15 
rs589566 2 21269809 1.41E-42 
 
rs67599264 2 21418083 1.59E-15 
rs1713223 2 21271270 1.91E-42 
 
rs11897480 2 21419320 1.60E-15 
rs12710748 2 21136327 3.30E-42 
 
rs568938 2 21303616 2.20E-15 
rs505403 2 21413961 3.63E-42 
 
rs10221876 2 21419809 2.24E-15 
rs12710750 2 21136564 3.83E-42 
 
rs504616 2 21414020 2.36E-15 
rs12710749 2 21136550 3.84E-42 
 
rs1878512 2 21420358 2.53E-15 
rs594677 2 21293006 1.20E-41 
 
rs478588 2 21297149 2.58E-15 
rs12468735 2 21275825 2.97E-41 
 
rs12712923 2 21421782 2.58E-15 
rs11892073 2 21276401 3.60E-41 
 
rs7578527 2 21422403 2.72E-15 
rs547186 2 21269241 4.27E-41 
 
rs17041988 2 21420697 3.16E-15 
rs512535 2 21267782 8.01E-41 
 
rs10205292 2 21426171 3.30E-15 
rs666126 2 21282435 1.48E-40 
 
rs17042000 2 21422928 3.39E-15 
rs565202 2 21297447 1.99E-40 
 
rs12712940 2 21426743 3.59E-15 
rs504618 2 21414019 3.23E-40 
 
rs34002646 2 21425323 3.85E-15 
rs666416 2 21304147 4.53E-40 
 
rs10169543 2 21423989 4.04E-15 
rs634292 2 21279909 5.91E-40 
 
rs503105 2 21315664 4.73E-15 
rs563476 2 21313676 4.18E-39 
 
rs4635554 2 21389659 1.20E-14 
rs675430 2 21311785 4.40E-39 
 
rs13414987 2 21141832 1.41E-14 
rs10206521 2 21420828 6.49E-39 
 
rs11693775 2 21296546 1.89E-14 
rs1878513 2 21420217 7.72E-39 
 
rs672889 2 21319016 2.00E-14 
 51 
rs6547409 2 21190209 1.55E-37 
 
rs72782148 2 21298547 2.10E-14 
rs76384951 2 21216112 4.16E-37 
 
rs11693760 2 21296492 2.13E-14 
rs571468 2 21293914 6.97E-36 
 
rs11673790 2 21299195 2.25E-14 
rs575905 2 21385538 1.59E-35 
 
rs1897083 2 21297051 2.38E-14 
rs4507059 2 21143329 7.98E-35 
 
rs17399144 2 21305685 2.38E-14 
rs540698 2 21416535 1.25E-34 
 
rs56350433 2 21298384 2.57E-14 
rs447986 2 21439498 3.93E-34 
 
rs4665176 2 21305853 2.83E-14 
rs385777 2 21439897 4.16E-34 
 
rs6708168 2 21301641 2.85E-14 
rs423836 2 21449098 4.89E-34 
 
rs61539677 2 21305195 2.93E-14 
rs384302 2 21443231 5.14E-34 
 
rs754523 2 21311691 2.99E-14 
rs679899 2 21250914 5.27E-34 
 
rs62122517 2 21298811 3.08E-14 
rs520354 2 21259612 8.75E-34 
 
rs62122520 2 21313430 3.30E-14 
rs387752 2 21444678 1.09E-33 
 
rs6761300 2 21306974 3.41E-14 
rs76423192 2 21185419 1.17E-33 
 
rs56079819 2 21314851 3.58E-14 
rs1429972 2 21309758 1.42E-33 
 
rs12477249 2 21400661 3.71E-14 
rs1429973 2 21309281 1.74E-33 
 
rs78120576 2 21318633 3.98E-14 
rs11694766 2 21426779 4.82E-33 
 
rs62120852 2 21213544 4.65E-14 
rs693 2 21232195 6.78E-33 
 
rs55938327 2 21209542 5.37E-14 
rs952275 2 21221399 1.51E-32 
 
rs1429974 2 21300770 6.34E-14 
rs597331 2 21262427 1.91E-32 
 
rs17399838 2 21368217 7.67E-14 
rs1041968 2 21232804 1.31E-31 
 
rs2337383 2 21320516 7.69E-14 
rs6725189 2 21219001 3.13E-31 
 
rs36018965 2 21383536 7.84E-14 
rs6756501 2 21218805 3.15E-31 
 
rs34916112 2 21339285 8.26E-14 
rs34776010 2 21216247 3.20E-31 
 
rs11693870 2 21320250 8.41E-14 
rs952274 2 21221357 3.21E-31 
 
rs754524 2 21311541 9.11E-14 
rs12992267 2 21215645 3.42E-31 
 
rs34872576 2 21326183 9.32E-14 
rs4665709 2 21220955 3.75E-31 
 
rs34882389 2 21381214 9.83E-14 
rs4371387 2 21221133 3.75E-31 
 
rs17395333 2 21323369 1.12E-13 
rs4503953 2 21105335 5.18E-31 
 
rs4665178 2 21321721 1.13E-13 
rs12710745 2 21112689 6.41E-31 
 
rs56090741 2 21323651 1.13E-13 
chr2:21290063 2 21290063 9.83E-31 
 
rs4665179 2 21321724 1.14E-13 
rs4305231 2 21111034 1.09E-30 
 
rs35913552 2 21272896 1.21E-13 
rs13392272 2 21217490 1.98E-29 
 
rs548145 2 21291312 1.22E-13 
rs452502 2 21442614 3.34E-29 
 
rs28562532 2 21309122 1.23E-13 
rs312050 2 21429198 3.42E-29 
 
rs481069 2 21281856 1.31E-13 
rs364390 2 21449787 3.42E-29 
 
rs668948 2 21291529 1.32E-13 
rs427642 2 21449940 3.45E-29 
 
rs541041 2 21294975 1.35E-13 
rs431802 2 21449791 3.48E-29 
 
rs7567217 2 21303470 1.37E-13 
rs437775 2 21438794 3.61E-29 
 
rs13011615 2 21274167 1.39E-13 
rs436941 2 21438863 3.63E-29 
 
rs581411 2 21289432 1.53E-13 
rs403772 2 21448480 3.70E-29 
 
rs563290 2 21288226 1.64E-13 
rs398532 2 21438480 3.72E-29 
 
rs562338 2 21288321 1.64E-13 
rs364381 2 21439753 3.72E-29 
 
rs580889 2 21290067 2.70E-13 
rs437624 2 21440004 3.75E-29 
 
rs10221768 2 21417431 2.97E-13 
rs384429 2 21447727 3.75E-29 
 
rs6756284 2 21309856 3.30E-13 
rs435647 2 21438180 3.78E-29 
 
rs312980 2 21377938 3.79E-13 
 52 
rs434540 2 21442574 3.84E-29 
 
rs62133262 2 21369926 3.84E-13 
rs414611 2 21446994 3.85E-29 
 
rs11687710 2 21371068 3.96E-13 
rs437362 2 21446845 3.87E-29 
 
rs2878956 2 21350346 4.67E-13 
rs426353 2 21442635 3.88E-29 
 
rs1800481 2 21267210 4.98E-13 
rs412255 2 21442733 3.92E-29 
 
rs67332771 2 21312210 5.14E-13 
rs3106202 2 21442855 3.94E-29 
 
rs72782173 2 21348958 5.26E-13 
rs454826 2 21443090 3.94E-29 
 
rs62135036 2 21348670 5.33E-13 
rs411617 2 21444950 3.94E-29 
 
rs17395512 2 21346556 5.70E-13 
rs430872 2 21443112 3.95E-29 
 
rs585967 2 21270554 5.83E-13 
rs427075 2 21443169 3.95E-29 
 
rs7568899 2 21345292 5.92E-13 
rs401211 2 21443465 3.95E-29 
 
rs111233436 2 21340378 6.26E-13 
rs427021 2 21451458 4.05E-29 
 
rs4352258 2 21452954 6.51E-13 
rs405983 2 21438129 4.34E-29 
 
rs71435593 2 21302020 6.58E-13 
rs393495 2 21450207 4.76E-29 
 
rs62135035 2 21346521 6.77E-13 
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